Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term pembrolizumab extension study in participants with advanced tumors
2017-004417-42Phase 3Active
- Sponsor
- Merck & Co.
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pembrolizumab in cancer, sponsored by Merck & Co. Primary endpoint: Overall survival. Started May 2018; status: active.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on 2017-004417-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004417-42.